|
ES2872555T3
(es)
*
|
2015-06-25 |
2021-11-02 |
Univ Health Network |
Inhibidores de HPK1 y métodos de uso de los mismos
|
|
US20180072718A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
|
IL292977A
(en)
|
2016-09-09 |
2022-07-01 |
Incyte Corp |
Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
|
|
US10280164B2
(en)
|
2016-09-09 |
2019-05-07 |
Incyte Corporation |
Pyrazolopyridone compounds and uses thereof
|
|
AR109595A1
(es)
|
2016-09-09 |
2018-12-26 |
Incyte Corp |
Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
|
|
WO2018152220A1
(en)
*
|
2017-02-15 |
2018-08-23 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
|
JP7132937B2
(ja)
|
2017-03-15 |
2022-09-07 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｈｐｋ１の阻害剤としてのアザインドール
|
|
BR112019018093A2
(pt)
|
2017-03-30 |
2020-06-16 |
F. Hoffmann-La Roche Ag |
Compostos, composição, método de inibição de hpk1, métodos para melhorar uma resposta imune e para tratar um distúrbio e usos do composto
|
|
SG11201908940UA
(en)
*
|
2017-03-30 |
2019-10-30 |
Hoffmann La Roche |
Isoquinolines as inhibitors of hpk1
|
|
WO2018228923A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
|
|
CA3066859A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
WO2018228925A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
US11427578B1
(en)
|
2017-07-18 |
2022-08-30 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
US10722495B2
(en)
|
2017-09-08 |
2020-07-28 |
Incyte Corporation |
Cyanoindazole compounds and uses thereof
|
|
CN109721620B
(zh)
*
|
2017-10-27 |
2022-05-13 |
药捷安康(南京)科技股份有限公司 |
Hpk1抑制剂及其用途
|
|
WO2019090198A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
JP7526673B2
(ja)
|
2018-02-20 |
2024-08-01 |
インサイト・コーポレイション |
がんを治療するためのｈｐｋ１阻害剤としてのｎ－（フェニル）－２－（フェニル）ピリミジン－４－カルボキサミド誘導体及び関連化合物
|
|
US10745388B2
(en)
|
2018-02-20 |
2020-08-18 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US10752635B2
(en)
|
2018-02-20 |
2020-08-25 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US11299473B2
(en)
|
2018-04-13 |
2022-04-12 |
Incyte Corporation |
Benzimidazole and indole compounds and uses thereof
|
|
TW202012405A
(zh)
*
|
2018-07-24 |
2020-04-01 |
瑞士商赫孚孟拉羅股份公司 |
萘啶化合物及其用途
|
|
TW202019905A
(zh)
|
2018-07-24 |
2020-06-01 |
瑞士商赫孚孟拉羅股份公司 |
異喹啉化合物及其用途
|
|
US10899755B2
(en)
|
2018-08-08 |
2021-01-26 |
Incyte Corporation |
Benzothiazole compounds and uses thereof
|
|
ES2973117T3
(es)
|
2018-09-25 |
2024-06-18 |
Incyte Corp |
Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
|
|
TW202024053A
(zh)
|
2018-10-02 |
2020-07-01 |
美商建南德克公司 |
異喹啉化合物及其用途
|
|
US11612606B2
(en)
|
2018-10-03 |
2023-03-28 |
Genentech, Inc. |
8-aminoisoquinoline compounds and uses thereof
|
|
CN113166062A
(zh)
*
|
2018-10-03 |
2021-07-23 |
豪夫迈·罗氏有限公司 |
8-氨基异喹啉化合物及其用途
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
PE20211655A1
(es)
|
2018-10-31 |
2021-08-24 |
Gilead Sciences Inc |
Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
|
|
WO2020092528A1
(en)
*
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
US20220047603A1
(en)
|
2018-12-11 |
2022-02-17 |
Bayer Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
ES2974634T3
(es)
|
2018-12-21 |
2024-06-28 |
Celgene Corp |
Inhibidores de tienopiridinas de RIPK2
|
|
CN113227100B
(zh)
*
|
2018-12-26 |
2023-05-05 |
詹森药业有限公司 |
噻吩并吡啶酮化合物
|
|
US12492194B2
(en)
|
2019-03-26 |
2025-12-09 |
Janssen Pharmaceutica Nv |
HPK1 inhibitors
|
|
CA3129772A1
(en)
|
2019-03-26 |
2020-10-01 |
Janssen Pharmaceutica Nv |
Bicyclic hpk1 inhibitors
|
|
US20220242870A1
(en)
*
|
2019-05-17 |
2022-08-04 |
Voronoi Inc. |
Heterocycle-fused pyrimidine derivative and use thereof
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
AU2020301161B2
(en)
|
2019-06-25 |
2023-10-26 |
Gilead Sciences, Inc. |
FLT3L-Fc fusion proteins and methods of use
|
|
TWI848141B
(zh)
|
2019-07-04 |
2024-07-11 |
英屬開曼群島商百濟神州有限公司 |
及其用途
|
|
CN112239473B
(zh)
|
2019-07-17 |
2023-12-08 |
百济神州(北京)生物科技有限公司 |
作为hpk1抑制剂的三环化合物的制备方法
|
|
KR20220059480A
(ko)
|
2019-08-06 |
2022-05-10 |
인사이트 코포레이션 |
고체 형태의 hpk1 억제제
|
|
PH12022550605A1
(en)
*
|
2019-09-13 |
2023-09-25 |
Nimbus Saturn Inc |
Hpk1 antagonists and uses thereof
|
|
CN112552293A
(zh)
*
|
2019-09-25 |
2021-03-26 |
珠海宇繁生物科技有限责任公司 |
一种protac小分子化合物及其应用
|
|
KR102902719B1
(ko)
|
2019-10-18 |
2025-12-24 |
포티 세븐, 엘엘씨 |
골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
|
|
CA3153636A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
EP4445902A3
(en)
|
2019-12-24 |
2024-12-18 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
EP4089096A4
(en)
*
|
2020-01-09 |
2024-01-03 |
Sumitomo Chemical Company, Limited |
HETEROCYCLIC COMPOUND AND MEANS THEREOF FOR CONTROLLING HARMFUL ARTHROPODS
|
|
CN117964757A
(zh)
|
2020-02-14 |
2024-05-03 |
吉利德科学公司 |
与ccr8结合的抗体和融合蛋白及其用途
|
|
MX2022012812A
(es)
*
|
2020-04-13 |
2023-01-30 |
Univ Health Network |
Métodos para tratar el síndrome de liberación de citocinas.
|
|
US12110294B2
(en)
|
2020-05-01 |
2024-10-08 |
Gilead Sciences, Inc. |
CD73 compounds
|
|
US12624049B2
(en)
|
2020-05-11 |
2026-05-12 |
University Health Network |
Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-z-yl)thieno[2.3-b]pyridin-6(7H)-one
|
|
WO2021249913A1
(en)
|
2020-06-09 |
2021-12-16 |
Bayer Aktiengesellschaft |
2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
|
|
CN113845531B
(zh)
*
|
2020-06-28 |
2025-06-27 |
四川科伦博泰生物医药股份有限公司 |
吡唑并环类化合物、包含其的药物组合物、其制备方法及其用途
|
|
TWI908894B
(zh)
*
|
2020-09-28 |
2025-12-21 |
南韓商福斯特生物股份有限公司 |
作為造血前驅細胞激酶１（ｈｐｋ１）抑制劑的吲唑及其用途
|
|
MX2023003731A
(es)
*
|
2020-09-30 |
2023-04-24 |
Beigene Ltd |
Compuestos de 3-[(1h-pirazol-4-il)oxi]pirazin-2-amina como inhibidores de hpk1, y uso de los mismos.
|
|
EP4240361A4
(en)
*
|
2020-11-09 |
2024-09-25 |
Merck Sharp & Dohme LLC |
INHIBITORS, OF THE 7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE TYPE, OF HPK1
|
|
CN116472041B
(zh)
*
|
2020-11-24 |
2024-12-06 |
正大天晴药业集团股份有限公司 |
氘修饰的噻吩并吡啶酮化合物
|
|
CN121851009A
(zh)
*
|
2021-01-22 |
2026-04-14 |
苏州信诺维医药科技股份有限公司 |
Hpk1抑制剂、其制备方法、药物组合物及其应用
|
|
US20240174683A1
(en)
|
2021-02-05 |
2024-05-30 |
Bayer Aktiengesellschaft |
Map4k1 inhibitors
|
|
CN114907377B
(zh)
*
|
2021-02-10 |
2026-05-12 |
江苏恒瑞医药股份有限公司 |
稠合四环类化合物、其制备方法及其在医药上的应用
|
|
WO2022174253A1
(en)
|
2021-02-12 |
2022-08-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
WO2022188823A1
(zh)
*
|
2021-03-10 |
2022-09-15 |
山东轩竹医药科技有限公司 |
三并环类hpk1抑制剂及其用途
|
|
WO2022199676A1
(zh)
*
|
2021-03-26 |
2022-09-29 |
江苏恒瑞医药股份有限公司 |
稠合四环类化合物、其制备方法及其在医药上的应用
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
JP2024517771A
(ja)
*
|
2021-04-30 |
2024-04-23 |
オンタリオ・インスティテュート・フォー・キャンサー・リサーチ（オーアイシーアール） |
造血前駆キナーゼ１（ｈｐｋ１）の阻害剤としての置換アミノアザヘテロアリール化合物
|
|
US20240425479A1
(en)
*
|
2021-04-30 |
2024-12-26 |
Ontario Institute For Cancer Research (Oicr) |
Halo-substituted amino aza-heteroaryl compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)
|
|
WO2022226667A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Ontario Institute For Cancer Research (Oicr) |
Substituted amino pyridine compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
WO2022253252A1
(en)
*
|
2021-06-03 |
2022-12-08 |
Silexon Biotech Co., Ltd. |
Heterocyclic compounds useful as hpk1 inhibitors
|
|
CN115433161A
(zh)
*
|
2021-06-04 |
2022-12-06 |
轶诺(浙江)药业有限公司 |
新型hpk1抑制剂及其制备方法和应用
|
|
WO2022258044A1
(zh)
*
|
2021-06-11 |
2022-12-15 |
杭州中美华东制药有限公司 |
吡咯并吡啶酮类化合物及其制备方法和用途
|
|
WO2022271650A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
MX2024000751A
(es)
*
|
2021-07-14 |
2024-03-25 |
Blueprint Medicines Corp |
Compuestos heterociclicos como inhibidores de map4k1.
|
|
EP4373817B1
(en)
|
2021-07-20 |
2025-05-21 |
Astrazeneca AB |
Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
|
|
US20250011331A1
(en)
*
|
2021-08-03 |
2025-01-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
WO2023023942A1
(en)
*
|
2021-08-24 |
2023-03-02 |
Biofront Ltd (Cayman) |
Hpk1 inhibitors, compositions comprising hpk1 inhibitor, and methods of using the same
|
|
WO2023057882A1
(en)
*
|
2021-10-05 |
2023-04-13 |
Pfizer Inc. |
Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
|
|
CA3233233A1
(en)
*
|
2021-10-15 |
2023-04-20 |
Ruben Abagyan |
Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof
|
|
AU2022375782B2
(en)
|
2021-10-28 |
2026-02-26 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
AU2022376954B2
(en)
|
2021-10-29 |
2026-04-23 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
WO2023107956A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
CN118339168A
(zh)
*
|
2021-12-17 |
2024-07-12 |
西藏海思科制药有限公司 |
一种并环杂环衍生物及其在医药上的应用
|
|
CA3237577A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CA3242099A1
(en)
*
|
2021-12-22 |
2023-06-29 |
Mark R. Bray |
Treatment for acute myeloid leukemia or lymphoma
|
|
AU2022419982B2
(en)
|
2021-12-22 |
2026-04-16 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
WO2023138612A1
(en)
*
|
2022-01-19 |
2023-07-27 |
Silexon Ai Technology Co., Ltd. |
Heterocyclic compounds useful as hpk1 inhibitors
|
|
CN118525026A
(zh)
*
|
2022-01-27 |
2024-08-20 |
西藏海思科制药有限公司 |
一种抑制或降解hpk1激酶的化合物及其在医药中的用途
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023151559A1
(zh)
*
|
2022-02-08 |
2023-08-17 |
和径医药科技（上海）有限公司 |
杂环化合物、包含其的药物组合物及其抗肿瘤应用
|
|
EP4493554A1
(en)
|
2022-03-17 |
2025-01-22 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
WO2023183817A1
(en)
|
2022-03-24 |
2023-09-28 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
CR20240451A
(es)
|
2022-04-21 |
2024-12-04 |
Gilead Sciences Inc |
Compuestos de modulación de kras g12d
|
|
PE20250758A1
(es)
|
2022-07-01 |
2025-03-13 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
CN117624187B
(zh)
*
|
2022-11-17 |
2025-11-04 |
杭州阿诺生物医药科技有限公司 |
一种高效的hpk1降解剂化合物及其制备方法和应用
|
|
KR102855849B1
(ko)
|
2022-11-25 |
2025-09-08 |
충남대학교산학협력단 |
이미다조피리딘 유도체, 이를 유효성분으로 포함하는 약제학적 조성물 및 이를 이용하는 암의 치료 방법
|
|
CN120225509A
(zh)
|
2022-12-22 |
2025-06-27 |
吉利德科学公司 |
Prmt5抑制剂及其用途
|
|
WO2024206869A2
(en)
*
|
2023-03-30 |
2024-10-03 |
Board Of Regents, The University Of Texas System |
Combination of hpk1 inhibitor and axl inhibitor in cancer therapy
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
PE20260121A1
(es)
|
2023-04-21 |
2026-01-16 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
KR20260046403A
(ko)
|
2023-07-26 |
2026-04-07 |
길리애드 사이언시즈, 인코포레이티드 |
Parp7 저해제
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
KR20250053739A
(ko)
*
|
2023-10-13 |
2025-04-22 |
주식회사유한양행 |
7,7-다이메틸푸로[3,4-b]피리딘-5(7H)-온 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
|
|
WO2025096647A1
(en)
*
|
2023-10-30 |
2025-05-08 |
Nimbus Saturn, Inc. |
Methods of treating tumors
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2026089992A1
(en)
|
2024-10-21 |
2026-04-30 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|